Valeant Pharmaceuticals International, Inc. (VRX) Shares Bought by Andra AP fonden

Andra AP fonden raised its position in Valeant Pharmaceuticals International, Inc. (NYSE:VRX) (TSE:VRX) by 35.0% during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 98,800 shares of the specialty pharmaceutical company’s stock after buying an additional 25,600 shares during the period. Andra AP fonden’s holdings in Valeant Pharmaceuticals International were worth $1,767,000 at the end of the most recent reporting period.

A number of other hedge funds have also recently bought and sold shares of the stock. Riggs Asset Managment Co. Inc. boosted its holdings in shares of Valeant Pharmaceuticals International by 118.2% during the 3rd quarter. Riggs Asset Managment Co. Inc. now owns 8,330 shares of the specialty pharmaceutical company’s stock worth $119,000 after purchasing an additional 4,512 shares during the last quarter. PNC Financial Services Group Inc. boosted its holdings in shares of Valeant Pharmaceuticals International by 33.7% during the 1st quarter. PNC Financial Services Group Inc. now owns 10,965 shares of the specialty pharmaceutical company’s stock worth $121,000 after purchasing an additional 2,763 shares during the last quarter. Financial Architects Inc boosted its holdings in shares of Valeant Pharmaceuticals International by 10.5% during the 2nd quarter. Financial Architects Inc now owns 10,550 shares of the specialty pharmaceutical company’s stock worth $183,000 after purchasing an additional 1,000 shares during the last quarter. Cetera Investment Advisers acquired a new position in shares of Valeant Pharmaceuticals International during the 2nd quarter worth approximately $192,000. Finally, IPG Investment Advisors LLC acquired a new position in shares of Valeant Pharmaceuticals International during the 2nd quarter worth approximately $203,000. Institutional investors own 46.61% of the company’s stock.

In other news, Director Schutter Richard U. De bought 10,000 shares of the stock in a transaction that occurred on Monday, August 21st. The stock was purchased at an average price of $14.33 per share, for a total transaction of $143,300.00. Following the completion of the purchase, the director now owns 77,479 shares in the company, valued at approximately $1,110,274.07. The purchase was disclosed in a legal filing with the SEC, which can be accessed through this link. Insiders own 5.87% of the company’s stock.

Valeant Pharmaceuticals International, Inc. (NYSE VRX) opened at $15.38 on Monday. The company has a debt-to-equity ratio of 4.84, a quick ratio of 1.03 and a current ratio of 1.26. The company has a market cap of $5,361.34, a price-to-earnings ratio of 2.50, a P/E/G ratio of 0.43 and a beta of -0.40. Valeant Pharmaceuticals International, Inc. has a 12 month low of $8.31 and a 12 month high of $18.71.

ILLEGAL ACTIVITY NOTICE: This piece was first posted by Chaffey Breeze and is the property of of Chaffey Breeze. If you are accessing this piece on another website, it was illegally stolen and republished in violation of international trademark & copyright laws. The legal version of this piece can be viewed at https://www.chaffeybreeze.com/2017/11/13/valeant-pharmaceuticals-international-inc-vrx-shares-bought-by-andra-ap-fonden.html.

Several research analysts have recently weighed in on the company. J P Morgan Chase & Co set a $10.00 target price on Valeant Pharmaceuticals International and gave the stock a “hold” rating in a report on Monday, July 17th. HC Wainwright reiterated a “hold” rating and issued a $17.00 price objective on shares of Valeant Pharmaceuticals International in a report on Wednesday, October 4th. Cantor Fitzgerald reiterated a “buy” rating and issued a $23.00 price objective on shares of Valeant Pharmaceuticals International in a report on Tuesday, August 29th. Wells Fargo & Company reiterated an “underperform” rating and issued a $9.00 price objective on shares of Valeant Pharmaceuticals International in a report on Thursday, August 10th. Finally, Deutsche Bank AG set a $19.00 price objective on Valeant Pharmaceuticals International and gave the company a “hold” rating in a report on Monday, August 21st. Five equities research analysts have rated the stock with a sell rating, eleven have given a hold rating, six have given a buy rating and one has assigned a strong buy rating to the company’s stock. The company currently has an average rating of “Hold” and a consensus price target of $17.17.

Valeant Pharmaceuticals International Company Profile

Valeant Pharmaceuticals International, Inc is a pharmaceutical and medical device company. The Company is engaged in developing and marketing a range of branded, generic and branded generic pharmaceuticals, over-the-counter (OTC) products, and medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment, and aesthetics devices).

Institutional Ownership by Quarter for Valeant Pharmaceuticals International (NYSE:VRX)

Receive News & Ratings for Valeant Pharmaceuticals International Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Valeant Pharmaceuticals International Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply